Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.

Melief CJ, van der Burg SH.
Nat Rev Cancer. 2008 May;8(5):351-60.

This Review deals with recent progress in the immunotherapy of established (pre)malignant disease of viral or non-viral origin by synthetic vaccines capable of inducing robust T-cell responses. The most attractive vaccine compounds are synthetic long peptides (SLP) corresponding to the sequence of tumour viral antigens or tumour-associated non-viral antigens. Crucial to induction of therapeutic T-cell immunity is the capacity of SLP to deliver specific cargo to professional antigen-presenting cells (dendritic cells (DC)). Proper DC activation then induces the therapeutic CD4+ and CD8+ T-cell responses that are associated with regression of established (pre)malignant lesions, including those induced by high-risk human papilloma virus.

URL: http://www.nature.com/nrc/journal/v8/n5/abs/nrc2373.html

Pub Med: http://www.ncbi.nlm.nih.gov/pubmed/18418403

created over 15 years ago (16 December 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]